Sobi shares drop 19 percent to around 106 million in the initial Monday trade after the morning announced that it is giving the cold shoulder to his attendants.
In late April conceded specialty pharmaceutical company that was in buddiskussioner but the board have now also completed discussions without reaching any agreement.
The company announces that it instead will continue preparations for the planned launch of blödarsjukeprojekten Elocta and Alprolix and building value through its growing and diverse portfolio.
No comments:
Post a Comment